TY - JOUR T1 - Cross-sectional and longitudinal characterization of SCD patients recruited from the community versus from a memory clinic: subjective cognitive decline, psychoaffective factors, cognitive performances, and atrophy progression over time. AU - Kuhn,Elizabeth, AU - Moulinet,Inès, AU - Perrotin,Audrey, AU - La Joie,Renaud, AU - Landeau,Brigitte, AU - Tomadesso,Clémence, AU - Bejanin,Alexandre, AU - Sherif,Siya, AU - De La Sayette,Vincent, AU - Desgranges,Béatrice, AU - Vivien,Denis, AU - Poisnel,Géraldine, AU - Chételat,Gaëlle, Y1 - 2019/07/08/ PY - 2018/12/20/received PY - 2019/06/13/accepted PY - 2019/7/10/entrez PY - 2019/7/10/pubmed PY - 2020/7/17/medline KW - Biomarkers KW - Neuroimaging KW - Pathological ageing KW - Preclinical Alzheimer’s disease KW - Psychoaffective factors KW - Subjective cognitive decline SP - 61 EP - 61 JF - Alzheimer's research & therapy JO - Alzheimers Res Ther VL - 11 IS - 1 N2 - BACKGROUND: Subjective cognitive decline (SCD) defines a heterogeneous population, part of which having Alzheimer's disease (AD). We aimed at characterizing SCD populations according to whether or not they referred to a memory clinic, by assessing the factors associated with increased AD risk. METHODS: Seventy-eight cognitively unimpaired older adults from the IMAP+ study (Caen) were included, amongst which 28 healthy controls (HC) and 50 SCD recruited from the community (SCD-community; n = 23) or from a memory clinic (SCD-clinic; n = 27). Participants underwent cognitive, psychoaffective, structural MRI, FDG-PET, and amyloid-PET assessments. They were followed up over a mean period of 2.4 ± 0.8 years. The groups were compared in terms of baseline and follow-up levels of SCD (self- and informant-reported), cognition, subclinical anxiety and depression, and atrophy progression over time. We also investigated SCD substrates within each SCD group through the correlations between self-reported SCD and other psychometric and brain measures. RESULTS: Compared to HC, both SCD groups showed similar cognitive performances but higher informant-reported SCD and anxiety. Compared to SCD-community, SCD-clinic showed higher informant-reported SCD, depression score, and atrophy progression over time but similar brain amyloid load. A significant increase over time was found for depression in the SCD-community and for self-reported praxis-domestic activities SCD factor in the SCD-clinic. Higher self-reported SCD correlated with (i) lower grey matter volume and higher anxiety in SCD-community, (ii) greater informant-reported SCD in SCD-clinic, and (iii) lower glucose metabolism in both SCD groups. CONCLUSIONS: Higher subclinical depression and informant-reported SCD specifically characterize the SCD group that refers to a memory clinic. The same group appears as a frailer population than SCD-community as they show greater atrophy progression over time. Yet, both the SCD groups were quite similar otherwise including for brain amyloid load and the SCD-community showed increased depression score over time. Altogether, our findings highlight the relevance of assessing psychoaffective factors and informant-reported SCD in SCD populations and point to both differences and similarities in SCD populations referring or not to a memory clinic. SN - 1758-9193 UR - https://www.unboundmedicine.com/medline/citation/31286994/Cross_sectional_and_longitudinal_characterization_of_SCD_patients_recruited_from_the_community_versus_from_a_memory_clinic:_subjective_cognitive_decline_psychoaffective_factors_cognitive_performances_and_atrophy_progression_over_time_ DB - PRIME DP - Unbound Medicine ER -